Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindemann JP, Macpherson MP, Neven P. Pritchard KI, et al. Among authors: lindemann jp. Breast Cancer Res Treat. 2010 Sep;123(2):453-61. doi: 10.1007/s10549-010-1022-9. Epub 2010 Jul 15. Breast Cancer Res Treat. 2010. PMID: 20632084 Clinical Trial.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R. Bergh J, et al. Among authors: lindemann jp. J Clin Oncol. 2012 Jun 1;30(16):1919-25. doi: 10.1200/JCO.2011.38.1095. Epub 2012 Feb 27. J Clin Oncol. 2012. PMID: 22370325 Clinical Trial.
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ. Robertson JF, et al. Among authors: lindemann jp. Breast Cancer Res Treat. 2012 Nov;136(2):503-11. doi: 10.1007/s10549-012-2192-4. Epub 2012 Oct 13. Breast Cancer Res Treat. 2012. PMID: 23065000 Clinical Trial.
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M. Patani N, et al. Among authors: lindemann j. Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10. Clin Cancer Res. 2014. PMID: 24916694 Free PMC article. Clinical Trial.
A good drug made better: the fulvestrant dose-response story.
Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. Robertson JF, et al. Among authors: lindemann j. Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Clin Breast Cancer. 2014. PMID: 25457991 Review.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Robertson JFR, et al. Clin Cancer Res. 2020 Apr 1;26(7):1574-1585. doi: 10.1158/1078-0432.CCR-19-3053. Epub 2019 Dec 13. Clin Cancer Res. 2020. PMID: 31836609 Free article. Clinical Trial.
279 results